Mevrometostat Medicine 03 June 2025 Extended indication Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Mevrometostat Domain Oncology Reason of inclusion New medicine (specialité) Main indication Prostate cancer Extended indication Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Pfizer Portfolio holder Pfizer Mechanism of action Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date November 2026 Expected Registration August 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van informatie fabrikant. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 2 times a day Dosage per administration 875mg References NCT06551324 (MEVPRO-1) Additional remarks Expected patient volume per year Patient volume 3,400 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Op basis van huidige gebruikersaantallen van abiraterone bij gemetastaseerd, castratieresistent prostaatcarcinoom worden er rond de 3.400 patiënten verwacht. Expected cost per patient per year Cost References Additional remarks De Nederlandse prijs is nog niet vastgesteld. Potential total cost per year Total cost Total cost for sluice Additional remarks Er is op dit moment niets bekend over de verwachte prijs en kosten. Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks